

Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: N/A	
Policy Number: PHW.PDL.063	Effective Date: 01/01/2020 Revision Date: 10/2021	
Policy Name: Lipotropics, Statins		
Type of Submission – <u>Check all that apply</u> :		
 □ New Policy □ Revised Policy* ✓ Annual Review - No Revisions ✓ Statewide PDL - Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL. 		
*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.		
Please provide any changes or clarifying information for the policy below:		
Q1 2022 annual review: no changes.		
Name of Authorized Individual (Please type or print): Venkateswara R. Davuluri, MD	Signature of Authorized Individual:	

CLINICAL POLICY Lipotropics, Statins



Clinical Policy: Lipotropics, Statins

Reference Number: PHW.PDL.063 Effective Date: 01/01/2020 Last Review Date: 10/2021

Policy/Criteria

Revision Log

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health and Wellness[®] that Statin Lipotropics are **medically necessary** when the following criteria are met:

I. Requirements for Prior Authorization of Lipotropic, Statins

A. Prescriptions That Require Prior Authorization

Prescriptions for a Lipotropic, Statin that meets any of the following conditions must be prior authorized:

- 1. A prescription for a non-preferred Lipotropic, Statin.
- 2. A prescription for a preferred Lipotropic, Statin with a prescribed quantity that exceeds the quantity limit.
- 3. A prescription for a Lipotropic, Statin when there is a record of a recent paid claim for another Lipotropic, Statin (therapeutic duplication)

B. <u>Review of Documentation for Medical Necessity</u>

In evaluating a request for prior authorization of a prescription for a Lipotropic, Statin the determination of whether the requested prescription is medically necessary will take into account the following:

- 1. For a non-preferred Lipotropic, Statin, whether the recipient has a history of therapeutic failure, contraindication or intolerance of the preferred Lipotropic, Statins.
- 2. For therapeutic duplication, whether:
 - a. The recipient is being titrated to, or tapered from, a drug in the same class

OR

b. Supporting peer reviewed literature or national treatment guidelines corroborate concomitant use of the medications being requested

OR



3. The recipient does not meet the clinical review guidelines listed above, but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

In addition, if a prescription for either a preferred or non-preferred Lipotropic, Statin is in a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the PA.CP.PMN.59 Quantity Limit Override.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above, to assess the medical necessity of the request for a prescription for a non-preferred Lipotropic, Statin. If the applicable guideline in Section B is met, the reviewer will prior authorize the prescription. If the applicable guideline is not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

D. Approval Duration: 12 months

Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020
Q3 2020 annual review: no changes.	07/2020
Q1 2021 annual review: no changes.	01/2021
Q1 2022 annual review: no changes.	10/2021